EFFICACY OF RIMEGEPANT AND ATOGEPANT IN MIGRAINE PROPHYLAXIS

I. CORRIENTE GORDÓN, E. PARADELA GARCIA, A. ROMERO RUIZ, E. SÁNCHEZ GÓMEZ, M.D. SANTOS RUBIO

Hospital Pharmacy. Juan Ramon Jimenez University Hospital. Ronda Norte Avenue, no number. 21005 Huelva, Spain.

OBJECTIVES

To assess the **efficacy of rimegepant and atogepant in migraine prophylaxis among outpatients at a tertiary-level hospital.**

Both drugs demonstrated efficacy in clinical trials (ADVANCE, PROGRESS, BHV3000-301/302/303).



METHODS

Retrospective observational study (July 2024 – March 2025).



42 outpatients initiating gepant treatment.

Variables: sex, age, treatment duration, prior prophylactics, monthly migraine days (MMD), adherence, ≥50% MMD reduction.



RESULTS

42 patients: **18** rimegepant, **24** atogepant

Treatment Duration	Prior Treatments
Rimegepant median: **9.4 weeks**	Atogepant median: **9.7 weeks**
Early discontinuation: **4.4 weeks**	Early discontinuation: **6.1 weeks**
Remainder: **12.9 weeks**	Remainder: **11.4 weeks**

88.1% women, median age **45** years

Median baseline MMD: **15.5 days**



25% achieved ≥50% MMD reduction

High adherence: **91.55%**

CONCLUSION

Despite the small cohort, response variability and modest clinical benefit suggest **uncertainty regarding efficacy**, with **no notable differences** between both gepants. The variation in MMD and ≥50% reduction rates during weeks 9–12 were **lower** for both drugs than those reported in CT.

4CPS-155





Institutional Affiliationy, of Palsmore Information If applicable